J . Org. Chem. 2000, 65, 4145-4152
4145
Syn th esis of th e C29-C44 P or tion of Sp on gista tin 1 (Altoh yr tin A)
Grier A. Wallace, Robert W. Scott, and Clayton H. Heathcock*
Department of Chemistry, University of California, Berkeley, California 94720
heathcock@cchem.berkeley.edu
Received February 29, 2000
Two synthetic approaches to the C29-C44 portion of spongistatin 1 (altohyritin A) have been
developed. The key step of the first approach relies on the Claisen rearrangement of glucal 18 to
provide ester 20a . This intermediate was advanced to silyl enol ether 30, which was coupled under
Mukaiyama aldol conditions with aldehyde 3. Cyclization of this aldol adduct completed our first
synthesis of the C29-C44 portion of spongistatin 1, requiring 25 total steps and occurring in 2.4%
yield over the longest linear sequence (21 steps). We have also developed a second-generation
approach based on the C-glycosidation of glucal 43. Through equilibration of the corresponding
C-glycosides 49a /b and 50a /b the desired C-glycoside (50a ) was obtained in good yield. Aldol
condensation of this ketone provided cyclization precursor 67, which undergoes acid-catalyzed
ketalization to close the E-ring of the spongistatins. An oxidation/reduction protocol was employed
to set the C37 stereocenter. Protection of the C37 carbonol and selective unmasking of the C44
carbonol completed our second generation synthesis. This approach requires 27 steps and occurred
in 13.2% yield over the longest linear sequence (18 steps).
In 1993 and 1994, isolations of the spongistatins,1
altohyrtins,2 and cinachyrolide A3 were reported. These
structurally related macrocyclic lactones show extreme
cytotoxicity toward various tumor cell lines, thus making
them valuable tools for understanding cancer. Spong-
istatin 1 has been identified as “probably the best to date
in the NCI’s evaluation programs,”4 exhibiting 50%
growth inhibition against a range of tumor lines at
concentrations in the range of 10-10 to 10-12 mol/L.
Additionally, this material has shown potent activity
against a subset of highly chemoresistant tumor types.4
Spongistatin appears to disrupt microtubule assembly by
binding tubulin in the vinca alkaloid binding site.5 The
compound also has potent antifungal properties, inhibit-
ing the growth of many fungi, including strains resistant
to amphotericin B, ketoconazole, and flucyosine.6
chemotherapy. The problem is that they are available
from Nature in only minute amounts and there is
currently no practical way to farm sponges to obtain
larger quantities of the metabolites. We believe that, even
despite their great complexity, conventional organic
synthesis can provide multigram quantities of the spong-
istatins, and it is the goal of the current project to develop
an efficient total synthesis to provide several grams of
the natural product so that a phase I clinical trial can
be carried out.
Because of their complex structures and extreme
cytotoxicity, these natural products have attracted the
attention of many groups,7 and two groups have already
recorded complete total syntheses. Evans and co-workers
reported the first total synthesis of spongistatin 2 and
proved it to be identical to altohyrtin C (2).8 Kishi has
published the total synthesis of altohyrtin A, which is
identical to spongistatin 1 (1).9
At the beginning of our synthetic efforts, we decided
to focus on altohyrtin A (1), since it was the only structure
whose absolute and relative configuration was supported
by adequate data. Our strategy was designed around a
macrolactonization as the final key step. Further discon-
nection of the C28-C29 double bond revealed two
similarly complex fragments, which were to be joined
using a Wittig reaction. We have previously described
our synthesis of the C1-C28 portion of spongistatin 1
(altohyrtin A).10 The C29-C51 fragment was envisioned
These extremely active marine natural products pro-
vide a good example of the power of Nature to point us
in the direction of organic structures of potential use in
(1) (a) Pettit, G. R.; Cichacz, Z. A.; Herald, C. L.; Gao, F.; Boyd, M.
R.; Schmidt, J . M.; Hamel, E.; Bai, R. J . Chem. Soc., Chem. Commun.
1994, 1605-1606. (b) Pettit, G. R.; Herald, C. L.; Cichacz, Z. A.; Gao,
F.; Boyd, M. R.; Christie, N. D.; Schmidt, J . M. Nat. Prod. Lett. 1993,
3, 239-244. (c) Pettit, G. R.; Herald, C. L.; Cichacz, Z. A.; Gao, F.;
Schmidt, J . M.; Boyd, M. R.; Christie, N. D.; Boettner, F. E. J . Chem.
Soc., Chem. Commun. 1993, 1805-1807. (d) Pettit, G. R.; Cichacz, Z.
A.; Gao, F.; Herald, C. L.; Boyd, M. R. J . Chem. Soc., Chem. Commun.
1993, 1166-1168. (e) Pettit, G. R.; Cichacz, A. A.; Gao, F.; Herald, C.
L.; Boyd, M. R.; Schmidt, J . M.; Hooper, J . N. A. J . Org. Chem. 1993,
58, 1302-1304.
(2) (a) Kobayashi, M.; Aoki, S.; Kitagawa, I. Tetrahedron Lett. 1994,
35, 1243-1246. (b) Kobayashi, M.; Aoki, S.; Sakai, H.; Kawazoe, K.;
Kihara, N.; Sasaki, T.; Kitagawa, I. Tetrahedron Lett. 1993, 34, 2795-
2798.
(3) Fusetani, N.; Shinoda, K.; Matsunaga, S. J . Am. Chem. Soc.
1993, 115, 3977-3981.
(4) Pettit, G. R. J . Nat. Prod. 1996, 59, 812-821.
(7) For a recent review, see: Pietruszka, J . Angew. Chem., Int. Ed.
Engl. 1998, 37, 2629-2636.
(8) (a) Evans, D. A.; Coleman, P. J .; Dias, L. C. Angew. Chem., Int.
Ed. Engl. 1997, 36, 2738-2741. (b) Evans, D. A.; Trotter, B. W.; Coˆte´,
B.; Coleman, P. J . Angew. Chem., Int. Ed. Engl. 1997, 36, 2741-2744.
(c) Evans, D. A.; Trotter, W. B.; Coˆte´, B.; Coleman, P. J .; Dias, L. C.;
Tyler, A. N. Angew. Chem., Int. Ed. Engl. 1997, 36, 2744-2747.
(9) (a) Guo, J .; Duffy, K. J .; Stevens, K. L.; Dalko, P. I.; Roth, R. M.;
Hayward, M. M.; Kishi, Y. Angew. Chem., Int. Ed. Engl. 1998, 37, 187-
192. (b) Hayward, M. M.; Roth, R. M.; Duffy, K. J .; Dalko, P. I.; Stevens,
K. L.; Guo, J .; Kishi, Y. Angew. Chem., Int. Ed. Engl. 1998, 37, 192-
196.
(5) (a) Bai, R.; Cichacz, Z. A.; Herald, C. L.; Pettit, G. R.; Hamel, E.
Mol. Pharmacol. 1993, 44, 757-766. (b) Bai, R.; Cichacz, Z. A.; Herald,
C. L.; Pettit, G. R.; Hamel, E. Proc. Annu. Meet. Am. Assoc. Cancer
Res. 1993, 34, 4: A2243. (c) Bai, R.; Taylor, G. F.; Cichaz, Z. A.; Herald,
C. L.; Kepler, J . A.; Pettir, G. R.; Hamel, E. Biochemistry 1995, 34,
9714-9721.
(6) Pettit, G. R. Patent Application WO97-US10200.
10.1021/jo0002801 CCC: $19.00 © 2000 American Chemical Society
Published on Web 06/02/2000